Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) have earned a consensus recommendation of “Buy” from the seven research firms that are covering the stock. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $15.89.

A number of research analysts have issued reports on NBRV shares. Zacks Investment Research downgraded Nabriva Therapeutics AG from a “buy” rating to a “hold” rating and set a $8.25 price objective for the company. in a research note on Friday, September 23rd. HC Wainwright started coverage on Nabriva Therapeutics AG in a research note on Thursday, September 8th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Wedbush restated an “outperform” rating and issued a $17.00 price objective on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th.

Several hedge funds and other institutional investors have recently modified their holdings of NBRV. Vivo Capital LLC purchased a new position in shares of Nabriva Therapeutics AG during the first quarter worth approximately $28,239,000. Opaleye Management Inc. boosted its position in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock worth $2,453,000 after buying an additional 53,800 shares in the last quarter. Finally, Jackson Park Capital LLC purchased a new position in shares of Nabriva Therapeutics AG during the second quarter worth approximately $195,000. 63.05% of the stock is currently owned by hedge funds and other institutional investors.

Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 7.1005 on Wednesday. Nabriva Therapeutics AG has a 52-week low of $6.61 and a 52-week high of $10.69. The firm has a 50-day moving average price of $7.50 and a 200-day moving average price of $7.92. The company’s market cap is $150.94 million.

Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.25) by $5.75. On average, analysts forecast that Nabriva Therapeutics AG will post ($1.93) EPS for the current year.

About Nabriva Therapeutics AG

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).

5 Day Chart for NASDAQ:NBRV

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.